Geode Capital Management LLC lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 5.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,272,261 shares of the biopharmaceutical company's stock after selling 143,089 shares during the quarter. Geode Capital Management LLC owned about 2.07% of Regeneron Pharmaceuticals worth $2,380,748,000 at the end of the most recent reporting period.
Several other large investors have also modified their holdings of REGN. Sequoia Financial Advisors LLC increased its position in shares of Regeneron Pharmaceuticals by 5.0% during the second quarter. Sequoia Financial Advisors LLC now owns 1,522 shares of the biopharmaceutical company's stock worth $1,600,000 after purchasing an additional 73 shares in the last quarter. Cooper Financial Group acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth $293,000. Diversified Trust Co grew its position in Regeneron Pharmaceuticals by 1.9% during the 2nd quarter. Diversified Trust Co now owns 1,209 shares of the biopharmaceutical company's stock worth $1,271,000 after purchasing an additional 22 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its position in Regeneron Pharmaceuticals by 2.1% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 23,634 shares of the biopharmaceutical company's stock valued at $24,840,000 after acquiring an additional 483 shares during the period. Finally, GPS Wealth Strategies Group LLC grew its stake in shares of Regeneron Pharmaceuticals by 16.0% in the 2nd quarter. GPS Wealth Strategies Group LLC now owns 594 shares of the biopharmaceutical company's stock valued at $625,000 after purchasing an additional 82 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.
Several analysts have recently commented on REGN shares. Wells Fargo & Company reduced their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an "overweight" rating for the company in a research note on Tuesday, October 22nd. Morgan Stanley cut their price objective on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating for the company in a research report on Friday, November 1st. StockNews.com lowered shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Monday, November 4th. Wolfe Research started coverage on shares of Regeneron Pharmaceuticals in a report on Friday, November 15th. They issued an "outperform" rating and a $1,150.00 price target for the company. Finally, Citigroup assumed coverage on Regeneron Pharmaceuticals in a research note on Thursday, November 14th. They set a "neutral" rating and a $895.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $1,107.29.
Get Our Latest Report on REGN
NASDAQ REGN opened at $788.00 on Tuesday. The company has a market cap of $86.59 billion, a P/E ratio of 19.50, a P/E/G ratio of 3.00 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a 12 month low of $735.95 and a 12 month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The company has a 50-day moving average of $871.59 and a 200-day moving average of $1,010.52.
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.